Your browser is no longer supported. Please, upgrade your browser.
Settings
ALKS Alkermes plc daily Stock Chart
ALKS [NASD]
Alkermes plc
Index- P/E- EPS (ttm)-1.17 Insider Own0.60% Shs Outstand159.39M Perf Week10.29%
Market Cap3.64B Forward P/E- EPS next Y-0.19 Insider Trans-25.77% Shs Float155.78M Perf Month9.50%
Income-182.50M PEG- EPS next Q-0.21 Inst Own97.70% Short Float3.54% Perf Quarter2.93%
Sales1.07B P/S3.41 EPS this Y-0.90% Inst Trans-1.25% Short Ratio4.03 Perf Half Y-34.04%
Book/sh6.95 P/B3.28 EPS next Y-147.10% ROA-10.30% Target Price28.00 Perf Year-42.75%
Cash/sh3.58 P/C6.38 EPS next 5Y0.92% ROE-16.20% 52W Range19.36 - 45.16 Perf YTD-22.64%
Dividend- P/FCF187.57 EPS past 5Y-56.50% ROI-7.70% 52W High-49.45% Beta1.83
Dividend %- Quick Ratio2.70 Sales past 5Y20.40% Gross Margin83.10% 52W Low17.92% ATR1.02
Employees2300 Current Ratio3.00 Sales Q/Q-8.10% Oper. Margin-14.00% RSI (14)57.01 Volatility5.81% 4.83%
OptionableYes Debt/Eq0.25 EPS Q/Q-27.10% Profit Margin-17.10% Rel Volume0.66 Prev Close22.30
ShortableYes LT Debt/Eq0.25 EarningsOct 24 BMO Payout- Avg Volume1.37M Price22.83
Recom2.70 SMA208.10% SMA504.28% SMA200-19.30% Volume907,911 Change2.38%
Sep-05-19Upgrade Morgan Stanley Underweight → Equal-Weight $30 → $20
Jul-15-19Upgrade Goldman Sell → Neutral
May-31-19Initiated H.C. Wainwright Neutral
May-01-19Downgrade Citigroup Buy → Neutral
Dec-19-18Downgrade Goldman Neutral → Sell
Dec-14-18Initiated Wolfe Research Underperform
Dec-13-18Downgrade Credit Suisse Outperform → Underperform
Nov-05-18Initiated Piper Jaffray Neutral $40
Aug-07-18Initiated Stifel Hold $15 → $45
Jun-21-18Downgrade Morgan Stanley Equal-Weight → Underweight
Jun-06-18Initiated B. Riley FBR, Inc. Buy $60
May-16-18Upgrade Citigroup Neutral → Buy
May-11-18Initiated BofA/Merrill Buy $56
Apr-02-18Downgrade Evercore ISI Outperform → In-line
Feb-22-18Downgrade Jefferies Buy → Hold
Oct-16-17Downgrade Barclays Overweight → Equal Weight $66 → $50
Jun-13-17Downgrade Leerink Partners Outperform → Mkt Perform
Oct-21-16Upgrade JP Morgan Neutral → Overweight
Oct-21-16Reiterated Leerink Partners Outperform $57 → $70
Oct-21-16Reiterated Jefferies Buy $62 → $70
Sep-13-19 07:15PM  Alkermes Plc (ALKS) Director and CEO, Alkermes plc Richard F Pops Sold $2.3 million of Shares GuruFocus.com
07:00AM  Alkermes Announces the Appointment of Richard Gaynor, M.D. and Andy Wilson to its Board of Directors and the Retirement of Director Floyd Bloom, M.D. PR Newswire
Sep-06-19 06:15PM  Alkermes Plc (ALKS) Director and CEO, Alkermes plc Richard F Pops Sold $2 million of Shares GuruFocus.com
Aug-24-19 09:31AM  Why Is Alkermes (ALKS) Down 3.9% Since Last Earnings Report? Zacks
Aug-19-19 02:19PM  An Intrinsic Calculation For Alkermes plc (NASDAQ:ALKS) Suggests It's 49% Undervalued Simply Wall St.
Aug-02-19 10:04AM  Clovis (CLVS) Q2 Earnings & Sales Lag Estimates, Shares Down Zacks
Jul-31-19 11:36AM  Biotech Stock Roundup: Celgene, Amgen, Gilead Impress in Q2, Other Pipeline Updates Zacks
Jul-30-19 03:05PM  Biogen Hedged Its Bet and Won Big Motley Fool +5.99%
07:30AM  Diroximel Fumarate Demonstrated Significantly Improved Gastrointestinal Tolerability Profile Compared to Dimethyl Fumarate in Patients with Multiple Sclerosis PR Newswire
07:30AM  Diroximel Fumarate Demonstrated Significantly Improved Gastrointestinal Tolerability Profile Compared to Dimethyl Fumarate in Patients with Multiple Sclerosis GlobeNewswire
Jul-29-19 12:30PM  Alkermes Announces Settlement With Amneal Over VIVITROL® Patent Dispute PR Newswire +6.32%
11:57AM  Edited Transcript of ALKS earnings conference call or presentation 25-Jul-19 12:00pm GMT Thomson Reuters StreetEvents
Jul-26-19 01:45PM  Alkermes Bounces Back -- but Not Enough Motley Fool
10:38AM  Alkermes (ALKS) Earnings and Sales Beat Estimates in Q2 Zacks
07:26AM  The Daily Biotech Pulse: Obseva Gets The Greenlight, Verastem Climbs On Licensing Deal, Merit Medical Earnings Disappoint Benzinga
Jul-25-19 05:23PM  Alkermes PLC (ALKS) Q2 2019 Earnings Call Transcript Motley Fool -8.74%
08:55AM  Alkermes (ALKS) Beats Q2 Earnings and Revenue Estimates Zacks
07:21AM  The Daily Biotech Pulse: Setback For Bristol-Myers Squibb, Gemphire Explodes, Lilly's Nasal Low Blood Sugar Drug Benzinga
07:00AM  Alkermes Plc Reports Second Quarter 2019 Financial Results PR Newswire
Jul-18-19 04:01PM  Alkermes to Host Conference Call to Discuss Second Quarter 2019 Financial Results PR Newswire +5.15%
11:23AM  Does Alkermes plc (NASDAQ:ALKS) Have A Particularly Volatile Share Price? Simply Wall St.
10:32AM  Earnings Preview: Alkermes (ALKS) Q2 Earnings Expected to Decline Zacks
Jul-17-19 10:06AM  Biotech Stock Roundup: Galapagos & Hookipa Surge, AMGN Shelves Alzheimer's Study Zacks
09:30AM  ALXN or ALKS: Which Is the Better Value Stock Right Now? Zacks
Jul-16-19 09:36AM  Alkermes to Include Bipolar I Disorder in ALKS 3831 NDA Zacks
Jul-15-19 07:00AM  Alkermes Expands Planned New Drug Application for ALKS 3831 to Include Treatment of Bipolar I Disorder PR Newswire
Jul-01-19 07:00AM  Alkermes Demonstrates Commitment to Local Community for 11th Consecutive Year With Largest Volunteer Event in Company History PR Newswire
Jun-25-19 09:30AM  CBM vs. ALKS: Which Stock Should Value Investors Buy Now? Zacks
Jun-18-19 03:42PM  Did You Manage To Avoid Alkermes's (NASDAQ:ALKS) Painful 56% Share Price Drop? Simply Wall St.
Jun-13-19 10:26AM  Alkermes Initiates Monothearpy Expansion Phase of ALKS 4230 Zacks
Jun-12-19 07:00AM  Alkermes Advances ALKS 4230 into Monotherapy Expansion Phase of ARTISTRY-1 in Patients With Renal Cell Carcinoma or Melanoma PR Newswire
Jun-11-19 11:04AM  Heres What Hedge Funds Think About Alkermes Plc (ALKS) Insider Monkey
Jun-06-19 09:30AM  CBM vs. ALKS: Which Stock Should Value Investors Buy Now? Zacks
May-31-19 09:07AM  Biogen Reports Interim Phase III Data on Diroximel Fumarate Zacks
May-30-19 07:30AM  New Phase 3 Interim Results Support Safety and Efficacy of Diroximel Fumarate in Multiple Sclerosis GlobeNewswire
May-29-19 10:34AM  Allergan's (AGN) Vraylar Gets FDA Nod for Bipolar Depression Zacks
May-25-19 09:31AM  Why Is Alkermes (ALKS) Down 21% Since Last Earnings Report? Zacks
May-22-19 11:34AM  Does Alkermes plc's (NASDAQ:ALKS) CEO Salary Compare Well With Others? Simply Wall St.
07:00AM  Alkermes to Present New Data From Mental Health Portfolio at the American Society of Clinical Psychopharmacology 2019 Annual Meeting PR Newswire
May-17-19 12:45PM  Edited Transcript of ALKS earnings conference call or presentation 25-Apr-19 12:30pm GMT Thomson Reuters StreetEvents
May-16-19 09:30AM  ALXN or ALKS: Which Is the Better Value Stock Right Now? Zacks
May-14-19 04:01PM  Alkermes to Present at the UBS Global Healthcare Conference PR Newswire
May-13-19 07:00AM  Alkermes to Showcase Leadership in Schizophrenia With New Data Presentations at Upcoming Scientific Conferences PR Newswire
Apr-26-19 03:58PM  Alkermes Looks Ahead to Growth Motley Fool
09:11AM  Alkermes PLC (ALKS) Q1 2019 Earnings Call Transcript Motley Fool
07:26AM  Alkermes (ALKS) Reports Narrower-Than-Expected Loss in Q1 Zacks
Apr-25-19 03:47PM  Biogen Looks to 23 Clinical Programs for Growth Motley Fool -12.78%
03:21PM  Here's Why Shares of Alkermes Sank Today Motley Fool
09:30AM  GILD vs. ALKS: Which Stock Is the Better Value Option? Zacks
07:58AM  The Daily Biotech Pulse: Adverum Gets New CFO, Flexion's Osteoarthritis Trial, Bristol-Myers Earnings Benzinga
07:00AM  Alkermes Plc Reports First Quarter 2019 Financial Results PR Newswire
06:30AM  Alkermes Plc to Host Earnings Call ACCESSWIRE
Apr-24-19 04:01PM  Alkermes Appoints Industry Veteran C. Todd Nichols as Senior Vice President of Sales and Marketing PR Newswire
01:43PM  Heres What Hedge Funds Think About Alkermes Plc (ALKS) Insider Monkey
Apr-19-19 01:37PM  Has Alkermes plc (NASDAQ:ALKS) Got Enough Cash? Simply Wall St.
Apr-18-19 04:00PM  Alkermes to Host Conference Call to Discuss First Quarter 2019 Financial Results PR Newswire
10:33AM  Earnings Preview: Alkermes (ALKS) Q1 Earnings Expected to Decline Zacks
Apr-11-19 07:48AM  The Daily Biotech Pulse: NASH Cheer For Intercept, Gilead Layoffs, BioDelivery Licenses Constipation Drug Benzinga
Apr-10-19 10:46AM  Alkermes Reports Positive Data From Schizophrenia Study Zacks
Apr-09-19 07:35AM  Alkermes says long-acting drugs could help schizophrenics stay on medication longer Reuters
07:00AM  Long-acting injectable drugs could help schizophrenics stay on medication longer Reuters
07:00AM  Alkermes Announces Positive Topline Results From Innovative Study of ARISTADA® and INVEGA SUSTENNA® for the Treatment of Schizophrenia PR Newswire
Apr-08-19 05:15PM  Alkermes Announces Departure of Jim Robinson PR Newswire
Apr-07-19 05:04PM  The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts Benzinga
Apr-03-19 07:00AM  Alkermes Expands Awards Program With Focus on Advancing Research in Schizophrenia PR Newswire
Apr-01-19 12:38PM  Drug companies that benefit from the war on opioid addiction Yahoo Finance
07:00AM  Alkermes to Present New ALKS 3831 Data From ENLIGHTEN-2 and Interim Extension Safety Study Results at 2019 Congress of the Schizophrenia International Research Society PR Newswire
Mar-26-19 11:51AM  Recro Pharma Falls as FDA Denies Approval to Pain Candidate Zacks
Mar-22-19 06:39PM  Top Insider Buys Highlight GuruFocus.com
Mar-21-19 09:54AM  Alkermes Focuses on Pipeline, Depends on Partners for Funds Zacks
Mar-20-19 09:00AM  Industry Consortium Launched to Qualify Biomarkers for Schizophrenia Drug Development Business Wire
Mar-16-19 09:30AM  Why Is Alkermes (ALKS) Up 4.7% Since Last Earnings Report? Zacks
Mar-13-19 03:42PM  Alkermes plcs (NASDAQ:ALKS) Path To Profitability Simply Wall St.
Mar-07-19 08:48AM  Allergan's Depression Candidate Fails in Studies, Stock Down Zacks
Mar-06-19 09:24AM  REVIEWAPALOOZA!: 5-Stock Samplers Motley Fool
Mar-05-19 04:01PM  Alkermes' Corporate Presentation to be Webcast at the Cowen and Company 39th Annual Health Care Conference PR Newswire
Feb-28-19 07:25AM  Research Report Identifies Sunoco LP, Citrix, Alkermes plc, CubeSmart, Morningstar, and Synopsys with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Feb-27-19 04:25PM  Biotech Stock Roundup: ONCE, CMTA Soar on Merger News, Other Pipeline Updates Zacks
Feb-26-19 08:32AM  Alkermes' (ALKS) and Biogen's NDA for BIIB098 Accepted by FDA Zacks
07:00AM  Alkermes Initiates Clinical Study of ALKS 4230 Administered Subcutaneously in Patients With Advanced Solid Tumors PR Newswire
Feb-25-19 05:54PM  CLASS ACTION UPDATE for IMMU, ALKS and SVXY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
03:49PM  FINAL DEADLINE - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against Alkermes plc, Inc. (ALKS) and Lead Plaintiff Deadline- February 25, 2019 ACCESSWIRE
02:30PM  CLASS ACTION UPDATE for YRIV, ALKS, MKL and AVP: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
12:48PM  FINAL DEADLINE - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alkermes plc, Inc. (ALKS) and Lead Plaintiff Deadline- February 25, 2019 ACCESSWIRE
11:29AM  CLASS ACTION UPDATE for DBVT, ALKS, GSM and MU: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
10:43AM  DEADLINE ALERT - IMMU, ALKS & DXC - Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE
07:30AM  Alkermes and Biogen Announce U.S. Food and Drug Administration Acceptance of Diroximel Fumarate New Drug Application for Multiple Sclerosis GlobeNewswire
Feb-24-19 02:48PM  DEADLINE - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alkermes plc, Inc. (ALKS) and Lead Plaintiff Deadline- February 25, 2019 ACCESSWIRE
02:21PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Alkermes plc. of Class Action Lawsuit and Upcoming Deadline - ALKS ACCESSWIRE
02:00PM  CLASS ACTION UPDATE for DNKEY, ALKS, ATVI and TAP: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
11:40AM  IMMU, ALKS & DXC - Bronstein, Gewirtz & Grossman, LLC Class Action Update ACCESSWIRE
10:57AM  FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of ALKS, GSM, UXIN and AVP GlobeNewswire
Feb-22-19 05:25PM  CLASS ACTION UPDATE for ALKS, MU, SVXY and UXIN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
03:00PM  DEADLINE ALERT -- Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alkermes plc, Inc. (ALKS) and Lead Plaintiff Deadline - February 25, 2019 ACCESSWIRE
02:07PM  Alkermes Public Limited Company Reminder: Pawar Law Reminds of Important February 25, 2019 Lead Plaintiff Deadline in Class Action ALKS GlobeNewswire
02:01PM  CLASS ACTION UPDATE for DBVT, AXGN, ALKS and SVXY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
01:05PM  Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Alkermes plc, Inc. (ALKS) GlobeNewswire
12:59PM  DEADLINE ALERT -- Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alkermes plc, Inc. (ALKS) and Lead Plaintiff Deadline: February 25, 2019 ACCESSWIRE
12:47PM  DEADLINE MONDAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
11:13AM  CLASS ACTION UPDATE for IMMU, ALKS, UXIN and AVP: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company's marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; and AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability. It is also developing BIIB098, a monomethyl fumarate, which is in Phase III clinical trials to treat relapsing forms of MS; ALKS 3831 to treat schizophrenia; ALKS 4230, an engineered fusion protein that is in Phase I clinical trials for cancer immunotherapy; and ALKS 5461 for the treatment of depressive disorders. The company has collaboration agreements with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International; license agreement with Acorda Therapeutics, Inc.; and license and collaboration agreement with Biogen Swiss Manufacturing GmbH. It also has a research collaboration with Clovis Oncology, Inc. to evaluate ALKS 4230 in combination with Clovis rucaparib, a PARP inhibitor and lucitanib, an investigational tyrosine kinase inhibitor. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
POPS RICHARD FDirector and CEO, Alkermes plcSep 12Option Exercise9.21100,000921,000816,433Sep 13 05:20 PM
POPS RICHARD FDirector and CEO, Alkermes plcSep 12Sale22.68100,0002,268,220716,433Sep 13 05:20 PM
POPS RICHARD FDirector and CEO, Alkermes plcSep 05Option Exercise9.21100,000921,000816,433Sep 06 05:01 PM
POPS RICHARD FDirector and CEO, Alkermes plcSep 05Sale20.18100,0002,017,830716,433Sep 06 05:01 PM
MITCHELL PAUL JDirectorJul 01Option Exercise8.987,00062,8607,000Jul 02 06:24 PM
Hopkinson Craig C.SVP, Med Dev/Med Affairs, CMOJun 07Option Exercise0.001,25007,245Jun 10 05:13 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 23Option Exercise8.5550,000427,500766,433May 24 08:09 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 23Sale24.2250,0001,211,150716,433May 24 08:09 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.May 22Option Exercise8.5520,000171,000205,122May 23 05:50 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.May 22Sale24.9320,000498,532185,122May 23 05:50 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 16Option Exercise8.5560,000513,000776,433May 24 08:09 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 16Sale25.4260,0001,525,278716,433May 24 08:09 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.May 09Option Exercise8.557,00059,85053,923May 13 05:54 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.May 09Sale26.895,373144,49848,550May 13 05:54 PM
Robinson James A. Jr.President & COO,Alkermes, Inc.Apr 04Option Exercise0.006,25006,250Apr 05 05:10 PM
MITCHELL PAUL JDirectorApr 01Option Exercise8.981,0008,9801,000Apr 02 07:00 PM
MITCHELL PAUL JDirectorApr 01Sale36.641,00036,6400Apr 02 07:00 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Mar 14Option Exercise8.5525,000213,750210,122Mar 14 06:53 PM
Wysenski NancyDirectorMar 14Buy33.0644514,7124,302Mar 18 05:05 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Mar 14Sale33.0525,000826,373185,122Mar 14 06:53 PM
POPS RICHARD FDirector and CEO, Alkermes plcMar 13Option Exercise8.5515,829135,338732,262Mar 14 06:38 PM
POPS RICHARD FDirector and CEO, Alkermes plcMar 13Sale33.5115,829530,485716,433Mar 14 06:38 PM
POPS RICHARD FDirector and CEO, Alkermes plcMar 12Option Exercise8.5544,171377,662760,604Mar 14 06:38 PM
POPS RICHARD FDirector and CEO, Alkermes plcMar 12Sale33.2444,1711,468,447716,433Mar 14 06:38 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Mar 07Option Exercise8.5520,000171,000205,122Mar 07 06:20 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Mar 07Sale32.0720,000641,362185,122Mar 07 06:20 PM
POPS RICHARD FDirector and CEO, Alkermes plcMar 05Option Exercise8.5550,000427,500766,433Mar 07 06:16 PM
POPS RICHARD FDirector and CEO, Alkermes plcMar 05Sale33.6350,0001,681,740716,433Mar 07 06:16 PM
MITCHELL PAUL JDirectorMar 01Option Exercise8.981,0008,9801,000Mar 04 05:13 PM
POPS RICHARD FDirector and CEO, Alkermes plcMar 01Option Exercise0.0017,5000724,203Mar 04 05:53 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Mar 01Option Exercise0.004,5000186,445Mar 04 05:50 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.Mar 01Option Exercise0.002,250047,585Mar 04 05:45 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSMar 01Option Exercise0.004,500051,044Mar 04 05:35 PM
Brown Iain MichaelSVP Finance & CAO, Alks Inc.Mar 01Option Exercise0.002,250031,064Mar 04 05:27 PM
MITCHELL PAUL JDirectorMar 01Sale33.481,00033,4800Mar 04 05:13 PM
POPS RICHARD FDirector and CEO, Alkermes plcFeb 26Option Exercise0.0010,0000710,590Feb 27 05:20 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Feb 26Option Exercise0.002,6250182,717Feb 27 05:18 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.Feb 26Option Exercise0.001,100045,659Feb 27 05:15 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSFeb 26Option Exercise0.002,625047,316Feb 27 05:12 PM
Brown Iain MichaelSVP Finance & CAO, Alks Inc.Feb 26Option Exercise0.001,100029,138Feb 27 05:08 PM
Wysenski NancyDirectorFeb 21Buy33.093,857127,6283,857Mar 18 05:05 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Feb 17Option Exercise0.003,0000180,965Feb 19 07:05 PM
POPS RICHARD FDirector and CEO, Alkermes plcFeb 17Option Exercise0.008,7500703,163Feb 19 07:12 PM
Brown Iain MichaelSVP Finance & CAO, Alks Inc.Feb 17Option Exercise0.002,500028,767Feb 19 06:51 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSFeb 17Option Exercise0.003,000045,566Feb 19 06:53 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.Feb 17Option Exercise0.002,500045,285Feb 19 06:56 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.Feb 16Option Exercise0.003,375043,893Feb 19 06:56 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSFeb 16Option Exercise0.003,375043,664Feb 19 06:53 PM
Brown Iain MichaelSVP Finance & CAO, Alks Inc.Feb 16Option Exercise0.002,375027,092Feb 19 06:51 PM
POPS RICHARD FDirector and CEO, Alkermes plcFeb 16Option Exercise0.0018,1250699,753Feb 19 07:12 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Feb 16Option Exercise0.003,3750179,074Feb 19 07:05 PM
Hopkinson Craig C.SVP, Med Dev/Med Affairs, CMOFeb 16Option Exercise0.003,37507,078Feb 19 07:03 PM
MITCHELL PAUL JDirectorFeb 01Option Exercise8.981,0008,9801,000Feb 01 05:01 PM
MITCHELL PAUL JDirectorFeb 01Sale32.731,00032,7300Feb 01 05:01 PM
MITCHELL PAUL JDirectorJan 04Option Exercise8.981,0008,9801,000Jan 04 06:01 PM
MITCHELL PAUL JDirectorJan 04Sale30.001,00030,0000Jan 04 06:01 PM
ANSTICE DAVID WDirectorDec 12Option Exercise8.9820,000179,60071,213Dec 13 06:30 PM
ANSTICE DAVID WDirectorDec 12Sale35.598,787312,71066,213Dec 13 06:30 PM
MITCHELL PAUL JDirectorDec 03Option Exercise8.981,0008,9801,000Dec 06 06:10 PM
MITCHELL PAUL JDirectorDec 03Sale36.451,00036,4500Dec 06 06:10 PM
MITCHELL PAUL JDirectorNov 02Option Exercise8.981,0008,9801,000Nov 02 05:22 PM
MITCHELL PAUL JDirectorNov 02Sale37.511,00037,5100Nov 02 05:22 PM
MITCHELL PAUL JDirectorOct 01Option Exercise8.981,0008,9801,000Oct 02 07:52 PM
MITCHELL PAUL JDirectorOct 01Sale42.421,00042,4200Oct 02 07:52 PM